These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16525179)

  • 1. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.
    Jaeckle KA; Ballman KV; Rao RD; Jenkins RB; Buckner JC
    J Clin Oncol; 2006 Mar; 24(8):1246-52. PubMed ID: 16525179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
    Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
    Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
    Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
    Ino Y; Betensky RA; Zlatescu MC; Sasaki H; Macdonald DR; Stemmer-Rachamimov AO; Ramsay DA; Cairncross JG; Louis DN
    Clin Cancer Res; 2001 Apr; 7(4):839-45. PubMed ID: 11309331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
    Cairncross G; Jenkins R
    Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
    Sonabend AM; Lesniak MS
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
    Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
    J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodendrogliomas: molecular biology and treatment.
    Bromberg JE; van den Bent MJ
    Oncologist; 2009 Feb; 14(2):155-63. PubMed ID: 19182242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in diagnosis and management of oligodendroglioma.
    Hussein MR; Baidas S
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):520-8. PubMed ID: 12382520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligodendroglioma.
    Van den Bent MJ; Reni M; Gatta G; Vecht C
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):262-72. PubMed ID: 18272388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic oligodendroglioma and oligoastrocytoma.
    van den Bent MJ
    Neurol Clin; 2007 Nov; 25(4):1089-109, ix-x. PubMed ID: 17964027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
    Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
    J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment paradigm for patients with anaplastic oligodendroglial tumors.
    Polivka J; Polivka J; Rohan V; Topolcan O
    Anticancer Res; 2014 Apr; 34(4):1587-94. PubMed ID: 24692686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
    Gadji M; Fortin D; Tsanaclis AM; Drouin R
    Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic markers as predictors of response to chemotherapy in gliomas.
    Idbaih A; Omuro A; Ducray F; Hoang-Xuan K
    Curr Opin Oncol; 2007 Nov; 19(6):606-11. PubMed ID: 17906460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
    Anderson MD; Gilbert MR
    Oncology (Williston Park); 2013 Apr; 27(4):315-20, 322. PubMed ID: 23781695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
    Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
    Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
    Born PW; Broholm H; Laursen H
    Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing management of low-grade astrocytomas and oligodendrogliomas.
    Agulnik M; Mason WP
    Hematol Oncol Clin North Am; 2006 Dec; 20(6):1249-66. PubMed ID: 17113461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.